ADORA3; | |
BCHE; ACHE; | |
CDK6; | |
CA2; CA1; CA12; CA9; CA7; CA4; | |
CBR1; AKR1B1; HSD17B10; | |
TP53; HIF1A; | |
ABCG2; | |
NPC1; MAPT; | |
XDH; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.586E-14 | 1.727E-10 | CA1, CA12, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.453E-13 | 1.055E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.368E-13 | 3.209E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.058E-12 | 2.198E-08 | CA1, CA12, CA2, CA4, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.180E-11 | 5.933E-08 | CA1, CA12, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.558E-11 | 6.189E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.860E-11 | 7.642E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.891E-11 | 1.069E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.723E-11 | 1.411E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.817E-10 | 3.408E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.267E-09 | 1.061E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.652E-09 | 5.709E-06 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 7.550E-08 | 4.326E-05 | BCHE, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 2.982E-07 | 1.381E-04 | AKR1B1, CYP19A1, CYP1A1, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.725E-07 | 2.100E-04 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.742E-06 | 6.656E-04 | ACHE, BCHE |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 3.148E-06 | 1.088E-03 | BCHE, CA2, CA9, CDK6, CYP1A1, CYP1A2, NPC1, TP53 |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 3.314E-06 | 1.127E-03 | BCHE, CA2, CA9, CYP1A1, CYP1A2, CYP1B1, NPC1, TP53 |
BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 3.373E-06 | 1.130E-03 | CA2, CYP1A1, CYP1A2, HIF1A, NPC1, TP53 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.766E-06 | 1.224E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.222E-06 | 1.602E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 5.222E-06 | 1.602E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 5.514E-06 | 1.668E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.044E-05 | 3.030E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.257E-05 | 3.554E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.738E-05 | 4.790E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.605E-05 | 6.752E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.605E-05 | 6.752E-03 | CA1, CA2 |
MF | GO:0003824; catalytic activity | GO:0016614; oxidoreductase activity, acting on CH-OH group of donors | 3.116E-05 | 7.891E-03 | AKR1B1, CBR1, HSD17B10, XDH |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.178E-14 | 2.320E-12 | CA12; CA1; CA2; CA4; CA7; CA9 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.260E-12 | 3.380E-10 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.166E-10 | 1.014E-08 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.080E-08 | 1.970E-07 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.212E-08 | 7.609E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.708E-06 | 1.671E-05 | CYP2C9; CBR1; CYP1A2; CYP1A1; AKR1B1; CYP2C19; CYP3A4; CYP19A1; HSD17B10; XDH |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.439E-06 | 1.671E-05 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.831E-06 | 1.671E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.866E-05 | 1.362E-04 | CYP1A2; CYP1A1; CYP1B1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.671E-05 | 2.436E-04 | CYP1A1; CYP1B1; CYP19A1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.010E-05 | 4.264E-04 | CYP2C9; CBR1; CYP2C19 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.051E-04 | 5.903E-04 | CA2; CYP3A4; ABCG2 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.397E-03 | 1.094E-02 | CDK6; TP53 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.214E-03 | 1.311E-02 | CDK6; TP53 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.312E-03 | 1.311E-02 | CDK6; TP53 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.624E-03 | 7.903E-03 | CYP3A4; XDH |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.411E-03 | 1.311E-02 | TP53; HIF1A |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.822E-03 | 1.329E-02 | CDK6; TP53 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.035E-03 | 1.339E-02 | CDK6; TP53 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.546E-03 | 1.991E-02 | CDK6; CYP1B1; TP53 |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 3.614E-03 | 1.319E-02 | CDK6; TP53 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.554E-03 | 1.763E-02 | CDK6; TP53 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.253E-03 | 2.702E-02 | CYP2C9; CYP2C19 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.439E-02 | 3.501E-02 | CDK6; HIF1A; TP53 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.023E-02 | 2.855E-02 | TP53; HIF1A |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.043E-04 | 2.108E-03 | CA2; CA4 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.056E-02 | 2.855E-02 | ADORA3; TP53 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.341E-02 | 3.375E-02 | CDK6; TP53 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.534E-02 | 3.612E-02 | CDK6; TP53 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.124E-02 | 2.932E-02 | CDK6; TP53 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.997E-02 | 4.557E-02 | MAPT; HSD17B10 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.621E-05 | 1.315E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
NA: NA | Edema | NA | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAPT |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
NA: NA | Upper abdominal bloating | NA | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; HIF1A; CA9 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; TP53; HIF1A; CA1; CA9; ACHE |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; CA1; CA1; AKR1B1; ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |